Sanofi-Aventis Receives Positive Final NICE Guidance On Multaq
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.